a
a
Weather:
No weather information available
HomeHealthSciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio

Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio

HANGZHOU, China, Jan. 10, 2025 /PRNewswire/ — Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration agreement for the global development and…

No comments

Sorry, the comment form is closed at this time.

Translate »